Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer
- 23 Downloads
We address the issue of modifiers of risk for persons who are, on average, at high risk of colorectal cancer due to carrying germline genetic mutations. We discuss how to estimate risk and assess modifiers using data from mutation-carrying families. A critical analytical issue is the adjustment for how families have been sampled (ascertainment). Only a few published studies have made appropriate adjustments and have mostly reported lifetime risks of less than 50%. Incomplete penetrance and differences in risk by subcategories are consistent with the existence of genetic and/or environmental risk modifiers. Data from large cohorts of carriers are required to study such modifiers with precision.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Last JM, ed.: A Dictionary of Epidemiology, 4th edn. New York: Oxford University; 2001.Google Scholar
- 5.Southey MC, Jenkins MA, Mead L, et al.: Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005, 23:6524–6532. This population-based study showed that immunohistochemistry testing, rather than testing for microsatellite instability or asking about family history, is the best way to triage early-onset colorectal cancer cases for MMR gene mutation testing.PubMedCrossRefGoogle Scholar
- 6.Hopper JL: Application of genetics to the prevention of colorectal cancer. Recent Results Cancer Res 2005, 166:17–33. This paper provides a broad discussion of familial and genetic aspects of colorectal cancer from the viewpoint of how new knowledge can be translated into public health benefit through prevention and better management.PubMedGoogle Scholar
- 8.Hopper JL, Southey MC, Dite GS, et al.: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999, 8:741–747.PubMedGoogle Scholar
- 18.Easton DF, Hopper JL, Thomas DC, et al.: Breast cancer risks for BRCA1/2 carriers. Science 2004, 306:2187–2191. This letter to the editor explains why the penetrance estimates for the BRCA1 and BRCA2 Ashkenazi founder mutations, previously published in Science, might be incorrect through problems in design and analysis.PubMedCrossRefGoogle Scholar
- 20.Quehenberger F, Vasen HFA, van Houwelingen HC: Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005, 42:491–496. This paper shows that, applying appropriate adjustment for ascertainement, the penetrance estimates for mismatch repair genes are considerably lower than previously thought.PubMedCrossRefGoogle Scholar
- 23.Jenkins MA, Baglietto L, Dowty JG, et al.: Cancer risks for carriers of germline mutations in hMLH1, hMSH2, hMSH6 and hPMS2: a population-based early-onset case-family study. Clin Gastroenterol Hepatol 2006, 4:489–498. This population-based study estimates the age-specific cumulative risks of colorectal and other cancers for MMR gene mutation carriers for the mutations that cause early-onset colorectal cancer.PubMedCrossRefGoogle Scholar